Fig. 3. SGF29 is essential to the maintenance of human leukemia xenografts in vivo.

(A) Schematic outline of a “human-in-mouse” leukemia xenograft model using NRGS mice (recipients) and the Cas9/luciferase-expressing human MOLM13 leukemic cells with or without SGF29 manipulation. (B) In vivo bioluminescent images of NRGS recipient mice transplanted with MOLM13-Cas9⁺/Luc⁺ leukemic cells with or without SGF29 manipulation (n = 9 mice per group). (C) Quantitative bioluminescent signal of NRGS recipient mice transplanted with MOLM13-Cas9⁺/Luc⁺ leukemic cells with or without SGF29 manipulation (n = 9 mice per group). (D) Kaplan-Meier survival curve of NRGS recipient mice transplanted with MOLM13-Cas9⁺/Luc⁺ leukemic cells with or without SGF29 manipulation (n = 9 mice per group). Data are represented as means ± SEM. *P < 0.01 by two-sided Student’s t test. I.V., intravenous.